Dr Reddy’s announces settlement of Revlimid capsules patent litigation with Celgene in US
Celgene has agreed to provide Dr Reddy’s with a license to sell volume-limited amounts of generic lenalidomide capsules in the US beginning on a confidential date after March 2022 subject to regulatory approval
Dr Reddy’s Laboratories announced the settlement of their litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb relating to patents for REVLIMID (lenalidomide) capsules.
In settlement of all outstanding claims in the litigation, Celgene has agreed to provide Dr Reddy’s with a license to sell volume-limited amounts of generic lenalidomide capsules in the US beginning on a confidential date after March 2022 subject to regulatory approval. The agreed-upon percentages are confidential. Dr Reddy’s is also licensed to sell generic lenalidomide capsules in the US without volume limitation beginning on January 31, 2026.
“We are pleased with the settlement agreement, and look forward to bringing a generic version of lenalidomide to market soon subject to regulatory approval for the benefit of patients,” says Marc Kikuchi, CEO, North America Generics, Dr Reddy’s Laboratories.
Revlimid is a trademark of Celgene, a wholly-owned subsidiary of Bristol Myers Squibb.
- Advertisement -